IQVIA (NYSE:IQV) Lowered to “Hold” Rating by StockNews.com

StockNews.com lowered shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a research report report published on Thursday.

Other analysts also recently issued reports about the company. Barclays reduced their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. BTIG Research reduced their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Leerink Partners reiterated an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Evercore ISI cut their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Truist Financial cut their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Stock Performance

Shares of IQV opened at $201.43 on Thursday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a 50-day moving average of $219.50 and a 200-day moving average of $226.40. The company has a market cap of $36.56 billion, a PE ratio of 26.43, a P/E/G ratio of 2.10 and a beta of 1.51. IQVIA has a one year low of $187.62 and a one year high of $261.73.

Institutional Investors Weigh In On IQVIA

A number of hedge funds have recently modified their holdings of the stock. Canada Pension Plan Investment Board raised its holdings in shares of IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares during the period. Farallon Capital Management LLC grew its stake in IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after buying an additional 86,870 shares in the last quarter. FMR LLC grew its stake in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares in the last quarter. Impax Asset Management Group plc grew its stake in IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in IQVIA by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock valued at $320,170,000 after buying an additional 11,715 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.